Nuvation Bio Wins FDA Approval for IBTROZI in ROS1+ Lung Cancer, but Shares Slide on Investor Uncertainty Nuvation Bio (NYSE: NUVB) announced that the U.S. Food and Drug Administration has approved IBTROZI (taletrectinib) for the treatment of adult patients with adv

#NUVB fell 16% despite FDA approved IBTROZI (taletrectinib) for adults with ROS1-positive non-small cell lung cancer.
#nuvationbioinc
prismmarketview.com/nuvation-bio...